alendronate has been researched along with Osteitis Deformans in 53 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteitis Deformans: A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.
| Excerpt | Relevance | Reference |
|---|---|---|
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 7.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| " Other end points included changes in urinary deoxypyridinoline excretion, pain, functional impairment scores, and radiological osteolysis." | 5.08 | Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. ( Altman, R; Conte, JM; Favus, M; Lombardi, A; Lyles, K; McIlwain, H; Murphy, WA; Reda, C; Rude, R; Seton, M; Siris, E; Thompson, D; Tiegs, R; Tucci, JR; Weinstein, RS; Yates, AJ; Zimering, M, 1996) |
| ") infusion of 5 mg alendronate was studied in ten patients with Paget's disease, six patients with primary hyperparathyroidism and ten osteopenic postmenopausal women." | 3.69 | Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. ( Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N, 1994) |
| "Although daily doses of oral bisphosphonates are a generally safe and effective treatment for Paget's disease of bone (PDB), some patients may experience upper gastrointestinal adverse events (UGI AEs) or find the dosing requirements inconvenient and become noncompliant." | 2.74 | Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. ( Faustino, A; Gilchrist, NL; Hooper, M; Hosking, D; Leung, A; Reid, IR; Salzmann, G; Selby, P; West, J; Wu, M, 2009) |
| "Alendronate was well tolerated, with an adverse event profile comparable with those of etidronate and placebo." | 2.69 | Alendronate in the treatment of Paget's disease of bone. ( Reid, IR; Siris, E, 1999) |
| " Study 1 is a retrospective study of 20 patients with moderate to severe disease who were treated with intravenous (iv) pamidronate (221 +/- 18 mg [SEM]; range 60-360 mg), and after biochemical remission and relapse were retreated with generally larger iv dosage (293 +/- 28 mg; range 180-600 mg)." | 2.69 | Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. ( Bhagat, CI; Criddle, A; Faulkner, DL; Gan, SK; Geelhoed, E; Gutteridge, DH; Kent, GN; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Vasikaran, S; Ward, LC; Will, RK, 1999) |
| "Alendronate was administered to 3 groups of 12 patients at doses of 2." | 2.68 | The effects of intravenous alendronate in Paget's disease of bone. ( Kanis, JA; Khan, S; McCloskey, EV; O'Doherty, DP; Vasikaran, S, 1995) |
| "Alendronate treatment normalized alkaline phosphatase in 48% of patients." | 2.68 | Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. ( Cundy, T; Dufresne, S; Hosking, DJ; Kotowicz, MA; Lombardi, A; Murphy, WA; Musliner, TA; Nicholson, GC; Reid, IR; Thompson, DE; Weinstein, RS; Yates, AJ; Yeap, S, 1996) |
| " Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome." | 2.44 | Paget disease of bone: therapeutic options. ( Silverman, SL, 2008) |
| "The early inhibition of bone resorption induces a reduction in serum calcium which leads to increased parathyroid hormone (PTH), and subsequently an increase in 1,25-dihydroxyvitamin D." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| " Whenever the initial dose failed to produce remission, the dosage was increased to twice a week the respective dose." | 1.51 | Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting. ( Abu Tailakh, M; Liel, Y, 2019) |
| "Paget disease of bone is the most common metabolic bone disease after osteoporosis, affecting 2-4% of adults over 55 years of age." | 1.38 | Paget disease of bone - an update. ( Britton, C; Walsh, J, 2012) |
| "Paget's disease of bone is a common metabolic bone disease in most of the European countries." | 1.38 | Polyostotic Paget's disease. ( Butt, R; Butt, ST; Fatima, S; Irfan, J; Jameel, G; Nasir, W, 2012) |
| "Alendronate is a potent aminobisphosphonate that has been used worldwide to decrease fracture risk in millions of post-menopausal women with and without osteoporosis, men with low bone mass, and in those with glucocorticoid- induced osteoporosis." | 1.35 | Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients. ( Tucci, JR, 2008) |
| "Etidronate treatment at 200 mg/day resulted in the improvement of bone metabolism markers and bone scintigraphy findings." | 1.32 | Two cases of monostotic Paget's disease: effects of bisphosphonate. ( Aoki, N; Harada, T; Hoshiro, M; Iwai, H; Miyatake, T; Nishimura, A; Ohno, Y, 2003) |
| "Alendronate seems to be a promising and safe agent for treatment of CIH." | 1.31 | Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. ( Bereket, A; Demir, E; Ozkan, B; Topçu, M, 2000) |
| "A 65-year-old woman with hemifacial spasm associated with Paget's disease was treated with alendronate, and the hemifacial spasm became very infrequent 4 months after commencement of the therapy." | 1.31 | The treatment with alendronate in hemifacial spasm associated with Paget's disease of bone. ( Fu, KK; Ko, A, 2000) |
| "The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed." | 1.31 | Case of an ivory vertebra. ( Ball, DW; Basaria, S; Belzberg, AJ; McCarthy, EF, 2000) |
| "All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%." | 1.29 | Acute effects of bisphosphonates on new and traditional markers of bone resorption. ( Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M, 1995) |
| "In a woman with postmenopausal osteoporosis, the infusion of alendronate (7." | 1.29 | The effect of alendronate on renal tubular reabsorption of phosphate. ( Gertz, B; Kahn, S; Kanis, JA; McCloskey, EV; O'Doherty, DP; Vasikaran, SD, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.77) | 18.7374 |
| 1990's | 19 (35.85) | 18.2507 |
| 2000's | 25 (47.17) | 29.6817 |
| 2010's | 6 (11.32) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Ralston, SH | 1 |
| Liel, Y | 2 |
| Abu Tailakh, M | 1 |
| Hooper, M | 1 |
| Faustino, A | 1 |
| Reid, IR | 3 |
| Hosking, D | 1 |
| Gilchrist, NL | 1 |
| Selby, P | 1 |
| Wu, M | 1 |
| Salzmann, G | 1 |
| West, J | 1 |
| Leung, A | 1 |
| Silverman, SL | 1 |
| Etemadi, J | 1 |
| Bagheri, N | 1 |
| Falaknazi, K | 1 |
| Ardalan, M | 1 |
| Rahbar, K | 1 |
| Nobakht Haghighi, A | 1 |
| Mohajel Shoja, M | 1 |
| Korkmaz, C | 1 |
| Britton, C | 1 |
| Walsh, J | 1 |
| Butt, ST | 1 |
| Fatima, S | 1 |
| Butt, R | 1 |
| Nasir, W | 1 |
| Jameel, G | 1 |
| Irfan, J | 1 |
| Bozkurt, D | 1 |
| Hiz, F | 1 |
| Çinar, M | 1 |
| Can, M | 1 |
| Carter, CJ | 1 |
| Ward, WG | 1 |
| Srivastava, AK | 2 |
| Mohan, S | 2 |
| Singer, FR | 1 |
| Baylink, DJ | 2 |
| Varadarajulu, S | 1 |
| Reddy, S | 1 |
| Noone, T | 1 |
| Payne, KM | 1 |
| Siris, E | 2 |
| Joshua, F | 1 |
| Epstein, M | 1 |
| Major, G | 1 |
| Hoshiro, M | 1 |
| Harada, T | 1 |
| Iwai, H | 1 |
| Miyatake, T | 1 |
| Nishimura, A | 1 |
| Ohno, Y | 1 |
| Aoki, N | 1 |
| Walsh, JP | 1 |
| Ward, LC | 3 |
| Stewart, GO | 2 |
| Will, RK | 2 |
| Criddle, RA | 1 |
| Prince, RL | 2 |
| Stuckey, BG | 3 |
| Dhaliwal, SS | 1 |
| Bhagat, CI | 2 |
| Retallack, RW | 2 |
| Kent, GN | 3 |
| Drury, PJ | 1 |
| Vasikaran, S | 4 |
| Gutteridge, DH | 3 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Brixen, KT | 1 |
| Abrahamsen, B | 1 |
| Kassem, MS | 1 |
| Mosekilde, L | 1 |
| Carter, G | 1 |
| Goss, AN | 1 |
| Doecke, C | 1 |
| Takada, J | 1 |
| Iba, K | 1 |
| Yamashita, T | 1 |
| Thomas, N | 1 |
| Rajaratnam, S | 1 |
| Shanthly, N | 1 |
| Oommen, R | 1 |
| Seshadri, MS | 1 |
| Letonturier, P | 1 |
| Tucci, JR | 2 |
| O'Doherty, DP | 4 |
| McCloskey, EV | 4 |
| Khan, S | 1 |
| Kanis, JA | 5 |
| Pedrazzoni, M | 2 |
| Alfano, FS | 1 |
| Gatti, C | 1 |
| Fantuzzi, M | 1 |
| Girasole, G | 2 |
| Campanini, C | 1 |
| Basini, G | 1 |
| Passeri, M | 2 |
| Vasikaran, SD | 2 |
| Gertz, B | 1 |
| Kahn, S | 1 |
| Adami, S | 2 |
| Zamberlan, N | 1 |
| Mian, M | 2 |
| Dorizzi, R | 1 |
| Rossini, M | 1 |
| Braga, B | 1 |
| Gatti, D | 1 |
| Bertoldo, F | 1 |
| Locascio, V | 1 |
| Rodan, GA | 1 |
| Balena, R | 1 |
| Shinkai, I | 1 |
| Ohta, Y | 1 |
| Weinstein, RS | 2 |
| Altman, R | 1 |
| Conte, JM | 1 |
| Favus, M | 1 |
| Lombardi, A | 3 |
| Lyles, K | 1 |
| McIlwain, H | 1 |
| Murphy, WA | 2 |
| Reda, C | 1 |
| Rude, R | 1 |
| Seton, M | 1 |
| Tiegs, R | 1 |
| Thompson, D | 1 |
| Yates, AJ | 2 |
| Zimering, M | 1 |
| Siris, ES | 1 |
| Nicholson, GC | 1 |
| Hosking, DJ | 1 |
| Cundy, T | 1 |
| Kotowicz, MA | 1 |
| Yeap, S | 1 |
| Dufresne, S | 1 |
| Musliner, TA | 1 |
| Thompson, DE | 1 |
| Khan, SA | 1 |
| Benéton, MN | 2 |
| Rogers, S | 1 |
| Coulton, L | 1 |
| Orgee, J | 1 |
| Coombes, G | 1 |
| Bonde, M | 1 |
| Garnero, P | 1 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Delmas, PD | 1 |
| Christiansen, C | 1 |
| Weihrauch, TR | 1 |
| Criddle, A | 1 |
| Price, RI | 1 |
| Faulkner, DL | 1 |
| Geelhoed, E | 1 |
| Gan, SK | 1 |
| Demir, E | 1 |
| Bereket, A | 1 |
| Ozkan, B | 1 |
| Topçu, M | 1 |
| Fu, KK | 1 |
| Ko, A | 1 |
| Wendlová, J | 1 |
| Galbavý, S | 1 |
| Paukovic, J | 1 |
| Basaria, S | 1 |
| McCarthy, EF | 1 |
| Belzberg, AJ | 1 |
| Ball, DW | 1 |
| Drake, WM | 1 |
| Kendler, DL | 1 |
| Brown, JP | 1 |
| Lim, EM | 1 |
| Umland, EM | 1 |
| Boyce, EG | 1 |
| MacFarlane, G | 1 |
| Srivastava, VP | 1 |
| Gertz, BJ | 1 |
| Tindale, W | 1 |
| Sciberras, DG | 1 |
| Survill, TT | 1 |
| Bickerstaff, DR | 1 |
| Hamdy, NA | 1 |
| Harris, S | 1 |
| Palummeri, E | 1 |
| Ciotti, G | 1 |
| Davoli, L | 1 |
| Pioli, G | 1 |
| Salvagno, G | 1 |
| Guarrera, G | 1 |
| Montesanti, F | 1 |
| Garavelli, S | 1 |
| Rosini, S | 1 |
| Lo Cascio, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone[NCT00480662] | Phase 3 | 60 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for alendronate and Osteitis Deformans
| Article | Year |
|---|---|
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; | 2008 |
[Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; | 2005 |
Bisphosphonates in the treatment of metabolic bone diseases.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Humans; Hyp | 1993 |
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Topics: Alendronate; Alkaline Phosphatase; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; | 2001 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
12 trials available for alendronate and Osteitis Deformans
| Article | Year |
|---|---|
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
Topics: Administration, Oral; Aged; Alendronate; Analysis of Variance; Bone Density Conservation Agents; Dou | 2009 |
Alendronate in the treatment of Paget's disease of bone.
Topics: Alendronate; Double-Blind Method; Female; Humans; Long-Term Care; Male; Osteitis Deformans; Treatmen | 1999 |
Bisphosphonate resistance in Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Clodronic Acid | 2003 |
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcium; | 2004 |
The effects of intravenous alendronate in Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Calcium; Diphospho | 1995 |
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids | 1996 |
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biopsy; Bone and B | 1996 |
Alendronate in the treatment of Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Biopsy; Calcium; Female; Humans; Hydroxyproline | 1997 |
Treatment of Paget's disease of bone with alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid; | 1999 |
Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.
Topics: Aged; Alendronate; Diphosphonates; Drug Resistance; Female; Humans; Male; Osteitis Deformans; Pamidr | 1999 |
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Calcium; Diphosphonates; Double-Blind Method; Drug Administ | 1992 |
Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Resorption; Clinical Trials as Topic; Dipho | 1990 |
35 other studies available for alendronate and Osteitis Deformans
| Article | Year |
|---|---|
Bisphosphonates in the management of Paget's disease.
Topics: Alendronate; Diphosphonates; Humans; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2020 |
Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Humans; Male; | 2019 |
Paget's disease of bone in a patient on hemodialysis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Female; Humans; Kidney Fa | 2008 |
Should we routinely evaluate serum alkaline phosphatase levels in patients with gout?
Topics: Alendronate; Alkaline Phosphatase; Allopurinol; Biomarkers; Colchicine; Drug Therapy, Combination; G | 2011 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2012 |
Polyostotic Paget's disease.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biopsy; Bone Density Conservation Agents; Humans; Male; Ost | 2012 |
[Headache case that responded to alendronate treatment in Paget's disease].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Headache; Humans; Male | 2012 |
Osteosarcoma diagnostic delay associated with alendronate-induced pain relief.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Errors; Humans; Mal | 2012 |
A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Amino Acid Sequence; Female; Humans; Middle Aged; Molec | 2002 |
Successful treatment of dysphagia in Paget's disease of the bone.
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Deglutition Disorders; Enteral Nutrition; | 2002 |
Two cases of monostotic Paget's disease: effects of bisphosphonate.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Diphosphonates | 2003 |
Alendronate-induced colon ulcers: case report of a new clinical entity.
Topics: Aged; Alendronate; Biopsy; Cecal Diseases; Cecum; Colon; Colonic Diseases; Colonoscopy; Diagnosis, D | 2004 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Remodel | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedu | 2005 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Dip | 2006 |
Paget's disease of bone: experience from a centre in southern India.
Topics: Adolescent; Adult; Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Child; | 2006 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients.
Topics: Absorptiometry, Photon; Aged, 80 and over; Alendronate; Bone Density; Calcium; Female; Fractures, Bo | 2008 |
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bon | 1995 |
The effect of alendronate on renal tubular reabsorption of phosphate.
Topics: Absorption; Aged; Alendronate; Calcium; Diphosphonates; Female; Glomerular Filtration Rate; Homeosta | 1994 |
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosp | 1994 |
Alendronate reaches U.S. market for osteoporosis, Paget's disease.
Topics: Alendronate; Diphosphonates; Female; Humans; Osteitis Deformans; Osteoporosis, Postmenopausal; Unite | 1995 |
New drugs--reports of new drugs recently approved by the FDA. Alendronate.
Topics: Alendronate; Animals; Clinical Trials as Topic; Diphosphonates; Female; Humans; Osteitis Deformans; | 1996 |
A potent new bisphosphonate for Paget's disease of bone.
Topics: Alendronate; Female; Humans; Male; Middle Aged; Osteitis Deformans | 1996 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
[Drug-induced esophagitis: can stringent indications help prevent this disease picture?].
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Female; Humans; Middle Aged; Osteitis Deformans; | 1997 |
Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia.
Topics: Adolescent; Alendronate; Biomarkers; Bone Remodeling; Chronic Disease; Humans; Male; Osteitis Deform | 2000 |
The treatment with alendronate in hemifacial spasm associated with Paget's disease of bone.
Topics: Aged; Alendronate; Brain; Evoked Potentials; Facial Muscles; Female; Hemifacial Spasm; Humans; Magne | 2000 |
[Paget's disease of bone--treatment with alendronate, calcium and calcitriol].
Topics: Aged; Alendronate; Calcitriol; Calcium; Drug Therapy, Combination; Humans; Male; Osteitis Deformans | 1999 |
Case of an ivory vertebra.
Topics: Alendronate; Alkaline Phosphatase; Biopsy; Bone Marrow; Carcinoid Tumor; Diagnosis, Differential; Di | 2000 |
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Topics: Alendronate; Calcitriol; Calcium; Cervical Vertebrae; Diphosphonates; Female; Humans; Hypocalcemia; | 2001 |
A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Amino Acid Sequence; Animals; Antibodies, M | 2001 |
Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Diphosphonates; Female; Humans; Male; M | 1989 |
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Topics: Alendronate; Alkaline Phosphatase; Clodronic Acid; Diphosphonates; Drug Resistance; Humans; Hydroxyp | 1986 |